On September 27, 2025, Imexpharm Corporation was proudly honored for the sixth consecutive year in Vietnam's 50 Best Performing Companies (TOP50). This recognition highlights Imexpharm’s agile management capabilities, strategic vision, resilience in the face of market challenges, and steadfast commitment to its mission of improving community healthcare in Vietnam.

Leveraging EU-GMP Production Capacity

Vietnam's 50 Best Performing Companies ranking is organized annually by Nhip Cau Dau Tu Magazine in collaboration with Thien Viet Securities, with advisory support from Harvard Business School experts. The list recognizes listed companies with outstanding performance on Vietnam’s stock market, based on three years of business results and three key indicators: revenue, return on equity (ROE), and earnings per share (EPS).
In 2025, Imexpharm was once again acknowledged for excellence in management, strategic foresight, and resilience amid a volatile market - delivering strong business results for the company and contributing positively to the local pharmaceutical industry. From 2022-2024, Imexpharm achieved a compound annual growth rate (CAGR) of 15.8% in net revenue. Its ROE reached 12.1%, 15.1%, and 15% over the three years, while EPS posted at VND 3,507, 4,381, and 2,864 billion, respectively.

With its industry-leading EU-GMP-certified production capacity (12 EU-GMP lines across three complexes) and 28 EU marketing authorizations for 11 products, combined with deep R&D investments and a continuous launch of innovative products, Imexpharm has sustained stable growth. In the first eight months of 2025, the company achieved VND 1,582 billion in net revenue (+18% YoY), fulfilling 60% of its annual plan.

During this period, Imexpharm further strengthened its position as a pioneer in producing and distributing high-quality pharmaceuticals, driving growth in both OTC and ETC channels. Comprehensive improvements in governance, production, and digital transformation enhanced productivity, ensured quality control, and optimized costs across its EU-GMP facilities. As a result, operating efficiency improved significantly: selling and administrative expenses were tightly managed, leading to profit before tax rising 23% to VND 261 billion, while EBITDA reached VND 344 billion (+18% YoY).

With stable operations, healthy profit margins, and consistent dividend payouts, Imexpharm’s stock (IMP) remains an attractive option for long-term investors seeking safety and sustainable growth. As of August 2025, the company’s market capitalization reached VND 8,286 billion.

Strategic Focus on High-Tech Pharmaceuticals

According to the organizers, Imexpharm is among the few listed companies that have consistently maintained sustainable growth and a presence in the TOP50 rankings. This success stems from its strategic investment of 5% of annual revenue into R&D, expansion of its product portfolio, and a strong focus on high-tech pharmaceuticals, a fast-growing industry trend.

With this foundation, Imexpharm is well-positioned to capture growth opportunities in Vietnam’s promising pharmaceutical market. According to IQVIA’s Vietnam Pharmaceutical Industry Report (Q2/2025), Vietnam’s pharmaceutical revenue reached USD 9.081 billion (+5%), surpassing Thailand (USD 8.657 billion) and the Philippines (USD 5.155 billion), securing the No. 1 position in Southeast Asia. Coupled with an aging population, rising incomes, and increasing healthcare demand, the high-value and high-tech pharmaceutical segment is expected to grow strongly.

This trajectory also aligns with Vietnam’s National Strategy for Pharmaceutical Industry Development to 2030, Vision 2045, which targets 80% domestic drug production (by volume), 70% market share (by value), at least 100 transferred innovative drugs, and USD 1 billion in exports. A key pillar is the development of pharmaceutical industrial zones to foster a closed ecosystem, enable technology transfer, and expand export opportunities.

In line with this strategy, Imexpharm’s Cat Khanh Pharmaceutical Factory Complex in Dong Thap (9.7 ha, VND 1,495 billion investment, EU-GMP certified) is designed to focus on strategic products such as biopharmaceuticals, biosimilars, advanced herbal medicines, and first generics. The project aims to provide stable, affordable treatments, easing the healthcare cost burden while addressing Vietnam’s “double burden”: the rise and rejuvenation of non-communicable diseases (cardiovascular, diabetes, obesity, digestive disorders) alongside persistent infectious disease risks (seasonal flu, chickenpox, mumps, rubella, dengue, etc.).

People’s Doctor, Pharmacist Tran Thi Dao, General Director of Imexpharm, shared: “Over the years, Imexpharm has consistently maintained steady revenue and profit growth, with a CAGR of 12.6% in net revenue from 2020–2024. This achievement comes from our EU-GMP-leading product quality, diverse portfolio meeting growing healthcare needs, and our deep investment strategy in R&D. Alongside expanding our network and continuously improving service quality, these efforts have enabled Imexpharm to operate efficiently and grow sustainably”.